Transgenic mice containing PAFR gene disruptions
OwnerThomas J. Brennan, William Matthews +1inventors
InventorsThomas J. Brennan, William Matthews, Mark Moore
Life of this patent
Estimating the term…
Abstract
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a platelet-activating factor receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Claims16
A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to a platelet-activating factor receptor gene;
- (b) a second polynucleotide sequence homologous to the platelet-activating factor receptor gene;
- and
- (c) a selectable marker.
A method of producing a targeting construct, the method comprising:
- (a) providing a first polynucleotide sequence homologous to a platelet-activating factor receptor gene;
- (b) providing a second polynucleotide sequence homologous to the platelet-activating factor receptor;
- (c) providing a selectable marker;
- and
- (d) inserting the first sequence, second sequence, and selectable marker into a vector, to produce the targeting construct.
A method of producing a targeting construct, the method comprising:
- (a) providing a polynucleotide comprising a first sequence homologous to a first region of a platelet-activating factor receptor gene and a second sequence homologous to a platelet-activating factor receptor gene;
- (b) inserting a positive selection marker in between the first and second sequences to form the targeting construct.
A cell comprising a disruption in a platelet-activating factor receptor gene.
A non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene.
A method of identifying an agent that modulates the expression of a platelet-activating factor receptor, the method comprising:
- (a) providing a non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene;
- (b) administering an agent to the non-human transgenic animal;
- and
- (c) determining whether the expression of platelet-activating factor receptor in the non-human transgenic animal is modulated.
A method of identifying an agent that modulates the function of a platelet-activating factor receptor, the method comprising:
- (a) providing a non-human transgenic animal comprising a disruption in a platelet-activating factor receptor gene;
- (b) administering an agent to the non-human transgenic animal;
- and
- (c) determining whether the function of the disrupted platelet-activating factor receptor gene in the non-human transgenic animal is modulated.
A method of identifying an agent that modulates the expression of platelet-activating factor receptor, the method comprising:
- (a) providing a cell comprising a disruption in a platelet-activating factor receptor gene;
- (b) contacting the cell with an agent;
- and
- (c) determining whether expression of the platelet-activating factor receptor is modulated.
A method of identifying an agent that modulates the function of a platelet-activating factor receptor gene, the method comprising:
- (a) providing a cell comprising a disruption in a platelet-activating factor receptor gene;
- (b) contacting the cell with an agent;
- and
- (c) determining whether the function of the platelet-activating factor receptor gene is modulated.
Dependencies are inferred from the claim text.